The Possible Osteoarthritis Disease Modifying Effect Of Trimetazidine In Rats

Abstract

Background: Osteoarthritis (OA) which is the most prevalent chronic joint disease and a primary contributor to pain and physical disability, impacting millions of individuals globally. It is primarily characterized by inflammation of the synovial membrane, degradation of articular cartilage, formation of osteophytes, and. remodeling of subchondral bone.

Aim: To evaluate OA disease modifying effect of trimetazidine administration on an experimental model of osteoarthritis. By assessment of histopathological changes, effect on autophagy, effect on apoptosis and the potential trimetazidine anti-inflammatory effect in rat model of osteoarthritis.

Design: The surgical induction of OA was performed on rats. The medial collateral ligament was exposed and transected through a medial midline skin incision, and the medial meniscus is reflected medially toward the femur and then cut.

The rats were divided into 3 groups as follow: group 1: control normal rats, group 2: osteoarthritic non treated rats and group 3: Trimetazidine treated osteoarthritic rats.

Results: Compared to the osteoarthritic non treated group, trimetazidine treated OA group showed a significant limitation of elevated histological score and histopathological changes, limitation of decreased LC3 expression, limitation of increased Caspase 3 expression and limitation of increased MMP-13, TNF-α and No.

 Conclusion: Trimetazidine could be a promising DMOAD. Accordingly, trimetazidine may be a good choice particularly for elderly patients who often have coexisting cardiovascular conditions alongside OA.  Possibly through enhancement of autophagic activity, inhibition of apoptosis, anti-inflammatory, anti-oxidative and anti-catabolic effect.